⭐️What happens when a Gyn Onc talks to a GU Onc at #ASCO24 . Dr. David O’Malley and I end up talking about the #ASCO24 data in PARP inhibitors, IO, ADCs, NGS, and clear cell cancers. Join us tonight on OncLive.com 👇
globalmeet.webcasts.com/starthere.jsp?…

The James Margaret Gatti-Mays MD MPH FACP

#ASCO24 Nancy Lin, MD of Dana-Farber’s Breast Oncology Center gave a provocative talk on #brainmets #clinicaltrials & endpoints. I think 🔑 issue is whether goal is drug approval (where drug’s contribution of effect must be demonstrated) vs simply improving pt outcomes via a multidisciplinary strategy.

Brilliant discussion on ctDNA in Breast Cancer abstracts by Dr. Daniel Stover Daniel Stover, MD, FASCO The James at #liquidbiopsy session
#ASCO24 ASCO
International Society of Liquid Biopsy

PEARLY

AC->T vs. AC -> Tcarbo among TNBC LN+ or 2cm

🔹7.2% ⬆️ in EFS w/ addition of carbo

🧐OS already very close to significant with 3.7% diff, p0.058

☑️Very compelling data that pCR translates to outcome in TNBC

#ASCO24
#bcsm

A-BRAVE adjuvant avelumab in TNBC.
Misses primary endpoint 5% 🔼PFS
Hits secondary endpoint 8.5% 🔼OS
What to do?
If you ‘reject” b/c of surrogate of PFS, you forsake a + result in more important endpoint of OS.
Challenges idea that ‘adjuvant’ IO doesn't work.

Great presentation by Shipra Gandhi Roswell Park from A011502 shows that patients with higher stress or pain had worse iDFS & OS in #breastcancer . PROs need to be added in all clinical trials! Roswell Park Hematology/Oncology Fellowship Oncology Brothers

A-BRAVE: adjuvant aveulmab after definitive treatment for high risk TNBC

❌DFS not significantly improved~5% numerically diff

✅ OS 8.5 months better!

✅ DDFS 7.5% better, HR 0.70

#ASCO24
#bcsm

“Fight for the things that you care about, but do it in a way that will lead others to join you.” RBG

OncoAlert 🚨is PROUD and We are Allies
#WomenInScience Leaders
Special Recognition Here to our Faculty @HopeRugo 🇺🇸 Nadia Harbeck,MD PhD 🇩🇪 Marina Garassino 🇺🇸 Erika Hamilton, MD 🇺🇸 in

Standing ovation for a very poignant and just beautiful opening session by Lynn M. Schuchter, MD, FASCO Dr. Lynn Schuchter “The art & science of cancer care: from comfort to cure”—it is all about our patients.

@ASCO #ASCO24

Outstanding discussion by Daniel Stover, MD, FASCO on #ctDNA : ctDNA is here - use with care. #ASCO2024 The James ASCO

Thanks to Margaret Gatti-Mays MD MPH FACP for stopping by our booth 12040 at #ASCO24 ! You can swing by for a chat and tell us why you’re a #SITC member too! #immunotherapy

Great discussion on #ctDNA by Daniel Stover, MD, FASCO! Sensitivity matters in #ctDNA detection! Liquid biopsy is not there yet to replace tissue biopsy! Need more studies to validate results! The James Ohio State Medical Oncology OncoAlert Oncology Brothers Margaret Gatti-Mays MD MPH FACP Sagar Sardesai Dionisia Quiroga, DO, PhD

Huge unmet need in #breastcancer - identifying effective treatment options for patients with leptomeningeal disease #LMD . Very nicely done study and encouraging results Erica Stringer-Reasor 👏👏

Is ER low metastatic #BreastCancer a TNBC-like disease subtype?

Check our circulating tumor DNA analysis

📍Poster Bd # 17 - Hall A, Metastatic Breast Cancer session
⏱️ 9:00 AM - 12:00 PM #ASCO24 #ctDNA #bcsm #liquidbiopsy

Aside from exciting data, one of my favorite things about #ASCO is the reunions with old friends and the meeting of new ones 🙂

Completely agree Daniel Stover, MD, FASCO 🙂

#ASCO24
Current HER2+ mBC treatment algorithm

T-DXd is close to becoming first-line (DB09).

From Dr. Ciara Catherine O'Sullivan's excellent discussion👇
OncoAlert

Getting ready to participate in this novel approach about where the field is today in #crcsm and impact of #UGI Plenary tomorrow on practice patterns. Oncology Brothers Margaret Gatti-Mays MD MPH FACP #medtwitter Vanderbilt-Ingram Cancer Center The James #ASCO24 @asco #cancer #cancer research MashupMediaMarketing

Mic’ed and getting ready to start with Oncology Brothers. Let’s talk about practing changing data in #breastcancer from #ASCO24 ASCO The James The Ohio State University Wexner Medical Center Ohio State Medical Oncology Pelotonia Institute for Immuno-Oncology

great job Marium Husain & Dr Chitnis 👏👏 on presenting clinical relevance of an easy-to-administer Promis 10 scale in clinic on prognosis and hospital admission rates in pts with sarcoma. The Ohio State University Wexner Medical Center The James Ohio State Medical Oncology